Fuchs Flávio D
Serviço de Cardiologia, Hospital de Clinicas de Porto Alegre, Ramiro Barcelos, 2350, 90.035-003, Porto Alegre, RS, Brazil.
Expert Rev Cardiovasc Ther. 2004 Sep;2(5):771-5. doi: 10.1586/14779072.2.5.771.
The risk of increasing blood pressure on the incidence of cardiovascular disease starts at 115/75 mmHg and roughly doubles for every 10 years increase in age, 20 mmHg increase in systolic blood pressure, 10 mmHg increase in diastolic blood pressure, or in the presence of comorbidities, such as diabetes or any evidence of cardiovascular disease. To lower blood pressure in patients with normal blood pressure and diabetes, or heart failure, or with any evidence of atherosclerotic disease in the coronary, cerebral and peripheral territories, reduces the incidence of major cardiovascular events by 18 to 42%. The diagnosis of hypertension in patients with these conditions is therefore irrelevant. The drugs that have mainly been tested in such conditions are the angiotensin-converting enzyme inhibitors, but their efficacy probably derives from their blood pressure-lowering effect, instead of a primary antiatherosclerotic effect.
血压升高对心血管疾病发病率的影响始于115/75 mmHg,并且随着年龄每增加10岁、收缩压升高20 mmHg、舒张压升高10 mmHg,或者存在合并症(如糖尿病或任何心血管疾病证据),风险大致翻倍。对于血压正常但患有糖尿病、心力衰竭或在冠状动脉、脑和外周血管存在任何动脉粥样硬化疾病证据的患者,降低血压可使主要心血管事件的发生率降低18%至42%。因此,在这些情况下诊断高血压并无意义。主要在此类情况下进行测试的药物是血管紧张素转换酶抑制剂,但其疗效可能源于其降压作用,而非主要的抗动脉粥样硬化作用。